Webinar Series: Cosmetics Supervision & Administration Regulation (CSAR)

June 30 - Sept. 15, 2022, 12 p.m. - 1:30 p.m. ET

Join PCPC and John Balzano, partner, Covington & Burling, for a new, three-part webinar series on the Chinese Government cosmetics reform law – Cosmetics Supervision and Administration Regulation (CSAR). 

CSAR, the Chinese Government cosmetics reform law, went into effect on Jan. 1, 2021. Since then, China has issued more than a dozen finalized CSAR secondary regulations and is working towards fully implementing the new law by 2023. CSAR significantly revises China’s cosmetics regulations, streamlining pre-market registration requirements in favor of an approach focused on registrants’ and filers’ responsibility and post-market enforcement.

  • Webinar 1: Overview and Q&A of CSAR’s critical elements, such as product and ingredient registration, animal testing exemption, labeling requirements, and implementation timeline of finalized regulations (June 30)
  • Webinar 2: China’s Good Manufacturing Practices Standard requirements and the potential implications for overseas manufacturers (July 28)
  • Webinar 3: CSAR Adverse Reaction Monitoring Rule and the new children’s cosmetic products regulatory regime (September 15)

The price for PCPC members is $745 and $1145 for nonmembers. Can’t make it to the webinars? Sign up anyway! Recordings will be sent to all registrants. For questions on registration, contact Shirley Gibbs.

About the Speaker

John Balzano
Partner, Covington & Burling

John Balzano has more than 15 years of experience with legal and regulatory issues related to China, particularly with regard to products regulated by the State Administration for Market Regulation, the National Medical Products Administration (NMPA) and other agencies in China, including drugs, devices and cosmetics, as well as food products and other agriculture, animal and healthcare products and services. He assists clients with developing strategies to obtain pre-market approvals for these products, including clinical development, understanding relevant pricing and reimbursement policies, and reviewing distribution and promotional plans.